(Acrixolimab)Biosimilar Reference Antibody-GS40008

货号：GS40008

Acrixolimab is a monoclonal antibody that has been investigated as an antineoplastic and immunotherapy agent. The drug is classified as a Programmed Cell Death 1 (PD-1) receptor antagonist, placing it in the category of immune checkpoint inhibitors. The proposed mechanism of action involves blocking the PD-1 receptor to release the "brake" on T cell activity, thereby restoring the immune system's ability to attack cancer cells. In addition to direct receptor antagonism, its mechanism is also associated with Antibody-Dependent Cell Cytotoxicity (ADCC), suggesting it may also promote the direct killing of target cells by immune effector cells. Acrixolimab was developed by Y-Biologics and has been studied for various advanced cancers.